Salima Brillman
Psychiatry · Sunnyvale, CANPI 1841292455
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $995,330 of the $1,397,543 with a category attached, or 71.2%. 28 manufacturers reported payments, led by MDD US Operations, LLC at 29.0% of the total. Among psychiatry clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,628 payments — averaging $858.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- MDD US Operations, LLC$405K
- Amneal Pharmaceuticals LLC$250K
- Neurocrine Biosciences, Inc.$133K
- Teva Pharmaceuticals USA, Inc.$122K
- Acorda Therapeutics, Inc$99K
- AbbVie$98K
- plus $291K from 22 others
Across 45 payments — averaging $6339.59 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amneal Pharmaceuticals LLC$138K
- AbbVie$53K
- H. Lundbeck A S$44K
- Integrative Research Laboratories Sweden AB$29K
- Acadia Pharmaceuticals Inc$16K
- Neurocrine Biosciences, Inc.$6K
What the payments were for
- Consulting fees$223,51716%
- Speaking & faculty fees$995,33071%
- Travel & lodging$146,37910%
- Food & beverage$24,5982%
- Education$7,7201%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| MDD US Operations, LLC | 522 | $405,320 |
| Amneal Pharmaceuticals LLC | 231 | $249,628 |
| Neurocrine Biosciences, Inc. | 167 | $133,288 |
| Teva Pharmaceuticals USA, Inc. | 113 | $122,394 |
| Acorda Therapeutics, Inc | 111 | $98,647 |
| AbbVie(2 entities) | 115 | $97,744 |
| Acadia Pharmaceuticals Inc | 116 | $83,284 |
| Adamas Pharmaceuticals, Inc. | 60 | $61,774 |
| Kyowa Kirin, Inc. | 56 | $60,093 |
| Lundbeck LLC | 47 | $38,837 |
| Cala Health, Inc. | 17 | $22,390 |
| Merz Pharmaceuticals, LLC | 19 | $14,401 |
| Sunovion Pharmaceuticals Inc. | 15 | $7,276 |
| Medtronic(2 entities) | 13 | $1,435 |
| Boston Scientific | 5 | $312 |
| Abbott | 2 | $169 |
| Supernus Pharmaceuticals, Inc. | 2 | $125 |
| UCB, Inc. | 3 | $103 |
| Ipsen Biopharmaceuticals, Inc | 3 | $84 |
| Bausch Health US, LLC | 2 | $44 |
| Revance Therapeutics, Inc. | 2 | $40 |
| Avanir Pharmaceuticals, Inc. | 1 | $30 |
| Catalyst Pharmaceuticals, Inc. | 1 | $28 |
| Biohaven Pharmaceuticals, Inc. | 1 | $26 |
| Impel Pharmaceuticals Inc. | 1 | $19 |
| Pfizer | 1 | $18 |
| Novartis | 1 | $18 |
| Otsuka America Pharmaceutical, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,397,543 in reported general payments places this provider in the 95th percentile of 4,954 psychiatry providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RytaryCarbidopa/Levodopa | 182 | $195,025 |
| NuplazidPimavanserin Tartrate | 27 | $133,018 |
| GocovriAmantadine Hcl | 40 | $72,944 |
| NourianzIstradefylline | 23 | $45,998 |
| NeuproRotigotine | 25 | $20,600 |
| QuliptaAtogepant | 14 | $17,221 |
| OngentysOpicapone | 15 | $9,782 |
| Rasagiline Mesylate | 56 | $6,998 |
| Diclofenac Potassium | 15 | $2,556 |
| Quetiapine Fumarate | 37 | $1,354 |
| RivastigmineRivastigmine Tartrate | 31 | $1,101 |
| Escitalopram Oxalate | 29 | $523 |
| Nortriptyline Hcl | 12 | $483 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 15 | $427 |
| AmantadineAmantadine Hcl | 11 | $425 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Amneal Pharmaceuticals LLCRytary | $249,628 | $195,025182 claims |
| Acadia Pharmaceuticals IncNuplazid | $83,284 | $133,01827 claims |
| MDD US Operations, LLCGocovri | $405,320 | $72,94440 claims |
| Kyowa Kirin, Inc.Nourianz | $60,093 | $45,99823 claims |
| UCB, Inc.Neupro | $103 | $20,60025 claims |
| AbbVieQulipta | $97,744 | $17,22114 claims |
| Neurocrine Biosciences, Inc.Ongentys | $133,288 | $9,78215 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,954 psychiatry providers in California.
Other psychiatry in Sunnyvale
- Gustavo AlvaOrange$5.8M
- John KooSan Francisco$3M
- Jason KelloggIrvine$2.7M
- Jonathan MeyerSan Diego$2.3M
- Charles Tuan-Tu NguyenIrvine$2.1M
- Manoj WaikarLos Gatos$1.9M
- Gerald MaguireSan Juan Capistraco$1.8M
- Bibi DasStanford$1.4M
- Konstantinos TripodisBurbank$1M
- Jason BermakSan Rafael$953K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.